Ayala Pharmaceuticals's revenue for the
three
months ended in Dec. 2023 was $0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01 Mil.
Ayala Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2023 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.
Warning Sign:
Ayala Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.
During the past 6 years, Ayala Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was -4.20% per year. The lowest was -82.50% per year. And the median was -43.35% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ayala Pharmaceuticals's Revenue
For the Biotechnology subindustry, Ayala Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ayala Pharmaceuticals's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Ayala Pharmaceuticals's Revenue falls into.
Ayala Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ayala Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADXS has been successfully added to your 